BACKGROUND AND AIMS: The treatment of submucosal (T1b) esophageal adenocarcinoma (EAC) remains in evolution, with some evidence supporting endoscopic management of low-risk lesions. Using a multicenter cohort, we evaluated outcomes of patients with T1b EAC and predictors of survival. METHODS: Patients diagnosed between 2001 and 2016 with T1b EAC were identified from 3 academic medical centers in the United States. Demographic, clinical, and outcome data were collected. Outcomes studied were overall and cancer-free survival. Cox proportional hazards models were constructed to assess independent predictors of survival. RESULTS: One hundred forty-one patients were included, of whom 68 (48%) underwent esophagectomy and 73 (52%) were treated endoscopically. Most patients (85.8%) had high-risk histologic features. Thirty-day operative mortality was 2.9%. Median follow-up in the esophagectomy and endoscopic cohorts was 49.4 and 43.4 months, respectively. Patients treated endoscopically were older with higher comorbidity scores, with 46 (63%) achieving histologic remission. Nineteen patients (26.0%) also received chemoradiation. Five-year overall survival rates in the surgical and endoscopic cohorts were 89% and 59%, respectively, whereas 5-year cancer-free survival rates were 92% and 69%. Presence of high-risk histologic features was associated with reduced overall survival. CONCLUSIONS: In this large multicenter study of patients with T1b EAC, esophagectomy was associated with improved overall but not cancer-free survival. High-risk histologic features were associated with poorer survival.
BACKGROUND AND AIMS: The treatment of submucosal (T1b) esophageal adenocarcinoma (EAC) remains in evolution, with some evidence supporting endoscopic management of low-risk lesions. Using a multicenter cohort, we evaluated outcomes of patients with T1b EAC and predictors of survival. METHODS:Patients diagnosed between 2001 and 2016 with T1b EAC were identified from 3 academic medical centers in the United States. Demographic, clinical, and outcome data were collected. Outcomes studied were overall and cancer-free survival. Cox proportional hazards models were constructed to assess independent predictors of survival. RESULTS: One hundred forty-one patients were included, of whom 68 (48%) underwent esophagectomy and 73 (52%) were treated endoscopically. Most patients (85.8%) had high-risk histologic features. Thirty-day operative mortality was 2.9%. Median follow-up in the esophagectomy and endoscopic cohorts was 49.4 and 43.4 months, respectively. Patients treated endoscopically were older with higher comorbidity scores, with 46 (63%) achieving histologic remission. Nineteen patients (26.0%) also received chemoradiation. Five-year overall survival rates in the surgical and endoscopic cohorts were 89% and 59%, respectively, whereas 5-year cancer-free survival rates were 92% and 69%. Presence of high-risk histologic features was associated with reduced overall survival. CONCLUSIONS: In this large multicenter study of patients with T1b EAC, esophagectomy was associated with improved overall but not cancer-free survival. High-risk histologic features were associated with poorer survival.
Authors: Hendrik Manner; Oliver Pech; Yvonne Heldmann; Andrea May; Michael Pauthner; Dietmar Lorenz; Annette Fisseler-Eckhoff; Manfred Stolte; Michael Vieth; Christian Ell Journal: Surg Endosc Date: 2014-10-08 Impact factor: 4.584
Authors: L Alvarez Herrero; R E Pouw; F G van Vilsteren; F J W ten Kate; M Visser; M I van Berge Henegouwen; B L A M Weusten; J J G H M Bergman Journal: Endoscopy Date: 2010-10-19 Impact factor: 10.093
Authors: Rami J Badreddine; Ganapathy A Prasad; Jason T Lewis; Lori S Lutzke; Lynn S Borkenhagen; Kelly T Dunagan; Kenneth K Wang Journal: Clin Gastroenterol Hepatol Date: 2009-11-27 Impact factor: 11.382
Authors: Ganapathy A Prasad; Tsung Teh Wu; Dennis A Wigle; Navtej S Buttar; Louis-Michel Wongkeesong; Kelly T Dunagan; Lori S Lutzke; Lynn S Borkenhagen; Kenneth K Wang Journal: Gastroenterology Date: 2009-06-12 Impact factor: 22.682
Authors: Annieke W Gotink; Fiebo Jc Ten Kate; Michael Doukas; Bas Pl Wijnhoven; Marco J Bruno; Leendert Hj Looijenga; Arjun D Koch; Katharina Biermann Journal: United European Gastroenterol J Date: 2018-12-06 Impact factor: 4.623